HARVARD BIOSCIENCE INC 8-K

What Happened

• Harvard Bioscience, Inc. (HBIO) filed an 8-K on March 10, 2026 reporting amended and restated employment agreements dated March 6, 2026 for CEO John Duke and for Mark Frost, who was appointed Chief Financial Officer and Treasurer effective March 6, 2026. Frost had served as Interim Financial Officer and Treasurer since April 10, 2025.

Key Details

• CEO John Duke: annual base salary $515,000 (subject to annual review beginning 2027); eligibility for a $100,000 cash payment in lieu of a FY2025 bonus tied to successful refinancing of the company’s credit facility; annual cash incentive up to 80% of base salary; 2026 target equity grant of 75,000 restricted stock units (RSUs), stated post the 1:10 reverse stock split effective March 13, 2026. Term extended to July 16, 2027 with automatic two-year extensions subject to agreement terms.
• CFO Mark Frost: annual base salary $375,000 (subject to annual review beginning 2027); annual cash incentive up to 60% of base salary; 2026 target equity grant of 30,000 RSUs (post-reverse split). Employment term through April 10, 2027 with similar automatic extension provisions.
• Both agreements include standard termination protections: accrued pay and vacation, possible target bonus payments, severance and accelerated vesting in certain events (e.g., termination without cause, resignation for good reason, change-in-control). Some payments require the executive to sign a general release.

Why It Matters

• These arrangements confirm continued leadership stability by extending the CEO’s term and formally naming the CFO, and they set clear compensation and incentive structures (salaries, cash incentives, and RSU targets) that align management with company performance and a credit-facility refinancing.
• For investors, the equity awards (75,000 and 30,000 RSUs post-reverse split) could affect future share-based dilution and management incentives; the $100,000 CEO payment is specifically tied to refinancing success, which signals focus on capital structure work. Termination and change-in-control severance terms are also material for assessing potential cash or equity payouts under certain scenarios.